Lyell Immunopharma, Inc. (LYEL) Market Cap & Valuation Ratios
Lyell Immunopharma, Inc. (LYEL) has a market cap of $230.1M and a price-to-sales ratio of 8522.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LYELLyell Immunopharma, Inc.Follow LYEL — free
—
Price chart with a free account
- Market cap
- 230.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LYEL | 0.2 | — | 963.0 | — | — | -55% | — | -142% |
| GALT | 0.3 | — | — | — | — | — | — | — |
| CTNM | 0.3 | — | — | — | — | — | — | -35% |
| TTRX | 0.3 | — | — | — | -1.4% | — | — | — |
| BNTC | 0.3 | — | — | — | -5.5% | — | — | — |
| PRLD | 0.3 | — | 6.2 | — | -11.5% | +220% | -301% | -86% |
| IRD | 0.3 | — | 24.0 | — | -12.2% | -36% | — | — |
| QNRX | 0.3 | — | — | — | -5.4% | — | — | — |
| AMRN | 0.3 | — | — | — | 6.0% | -15% | -22% | -13% |
| ABEO | 0.3 | — | 4.7 | — | — | — | -328% | -157% |
| EVMN | 0.2 | — | — | — | — | +86% | — | -47% |
| Median of these 10 | — | 6.2 | — | -5.5% | +35% | -301% | -47% |
; EV/Sales 963.0 vs. 6.2.
Growth vs. price
each dot a company · hover or tap for valuesLyell Immunopharma, Inc. — questions
- What is Lyell Immunopharma, Inc.'s market cap?
- $230.1M.
- What is Lyell Immunopharma, Inc.'s price-to-sales ratio?
- 8522.3.
Every figure on this page comes from Lyell Immunopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.